Genetic risk tied to IBD severity

While genome-wide association studies have successfully identified over 240 genetic loci associated with the onset of inflammatory bowel disease (IBD), the clinical utility of these markers in predicting long-term disease behavior has remained a subject of ongoing debate. A significant nationwide cohort study from Denmark, involving 8,261 patients, has now clarified this relationship by demonstrating that a patient’s cumulative genetic burden measured through a polygenic risk score (PGS) is a potent predictor of disease severity. By categorizing patients into risk quintiles, researchers found that those with the highest genetic predisposition were more than twice as likely to require major abdominal surgery and consistently exhibited higher levels of fecal calprotectin, a key biomarker of active intestinal inflammation.

The study further highlights distinct mechanistic differences in how these genetic risks manifest within the two primary forms of IBD. In Crohn’s disease, the link between a high polygenic risk and clinical severity appears to be largely mediated by the anatomical location of the disease, such as ileal involvement, which naturally carries a higher risk for complications. In contrast, for patients with ulcerative colitis, the genetic burden serves as an independent predictor of an aggressive disease course, regardless of the initial extent of the inflammation. These findings suggest a shift toward a precision medicine framework in gastroenterology, where genetic profiling at the point of diagnosis could allow clinicians to identify high-risk individuals and implement more aggressive, “top-down” therapeutic strategies to prevent long-term bowel damage and surgical intervention

To read more, visit GI & Hepatology News

https://news.gastro.org/issues/2026/february/genetic-risk-tied-to-ibd-severity/